It’s been quite entertaining lately to watch some Americans waddle around whinging about how oppressed they are, when it’s apparent that none of them have ever visited an actual dictatorship. In many of the 50 remaining dictatorships on this planet, people often starve, yet in the U.S. there seems to be too much food available. […]
We’re halfway through 2019 and we’ve seen a ton of high-profile startups IPO this year. However, few of those joining the ranks of public companies represent a pure play in the sort of emerging technologies that we cover here at Nanalyze. That’s especially been the case with companies where artificial intelligence is at the core […]
Former Vice President Al Gore was back in the news this month, raising millions for a new campaign. No, not the one crowded with 22 candidates and counting. His Generation Investment Management firm just raised $1 billion for what those who know anything about impact investing might call a do-gooder fund. Socially responsible investing, which […]
If you’ve ever taken an introductory cultural anthropology class, you might recall reading a paper on “Body Ritual among the Nacirema.” Written in 1956, it’s an account of an anthropologist who visits a tribe and observes all kinds of weird behavior – like medicine men who jab coated needles into the flesh of the natives. […]
Diabetes doesn’t cause nearly as much of a stir in the media compared to HIV or cancer, but a few well-known names are associated with the disease – Halle Berry, Tom Hanks, and Paula Deen. And who doesn’t love that Food Network maven and American celebrity chef? Scandals aside, diabetes comes in two versions – Type […]
This past week, Google (NASDAQ:GOOGL) announced their intention to work with Dexcom (NASDAQ:DXCM) to create a glucose monitor that is easy to afford and maintain and which does not involve the need for a blood sample. For people that suffer from diabetes, monitoring their glucose levels has been a painful practice that involves pricking one’s finger and […]
The biotech industry has been kind to investors over the past year with the SPDR S&P Biotech ETF (XBI) up over +75% in the past year compared to an +8.7% increase over the same time frame for the S&P 500. Biotech IPOs have been even hotter with 2014 setting an all-time record both in the number of […]